Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290
Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $290.
Stocks · News reference
9 Of 11 Sectors Fall Wednesday As Defensives Lead
Two of 11 sectors are higher in Wednesday's regular session, with defensive sectors holding the top three positions. The leaders are separated rather than clustered, with Health Care and Consumer Staples above the rest of the table.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why is AbbVie (ABBV) Stock Trending After Hours?
AbbVie Inc. Shares rose 0.44% after hours following FDA breakthrough designations for telisotuzumab adizutecan in two cancers.
Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $310
Morgan Stanley analyst Terence Flynn maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $296 to $310.
TD Cowen Reinstates Hold on Bank of America, Announces $60 Price Target
iShares U.S. Financials ETF vs State Street SPDR Bank ETF: Which Is the Better Buy?
The article compares two financial sector ETFs: iShares U.S. Financials ETF (IYF) and State Street SPDR Bank ETF (KBE). IYF offers broader financial services exposure with 143 holdings and has delivered superior five-year returns ($1,626 vs $1,347 on $1,000 invested), proving more resilient during market downturns. KBE focuses narrowly on banking with 107 holdings, offers a higher dividend yield (2.30% vs 1.53%), and has a slightly lower expense ratio, but experienced deeper drawdowns. The article recommends IYF for long-term growth investors seeking quality large-cap financials, while KBE may suit income-focused investors prioritizing yield.
Why C.H. Robinson Stock Was Sliding Again Today
C.H. Robinson's stock fell 4.3% today following a 11% drop yesterday after announcing its acquisition of RXO for approximately $3 billion. Wall Street analysts Bank of America and Evercore lowered their price targets, citing concerns about capital dilution and deal timing, though both maintained buy-equivalent ratings. The company plans to suspend share buybacks and take on new debt to fund the acquisition, but expects the deal to be earnings accretive within nine months if it can achieve $300 million in synergies.